Soleno reports new data on VYKAT XR for Prader-Willi syndrome

Soleno Therapeutics (SLNO) presented new clinical data for its FDA-approved VYKAT XR, demonstrating statistically significant and clinically meaningful reductions in hyperphagia symptoms in Prader-Willi syndrome (PWS) patients, including those with pre-diabetes/diabetes, with a manageable safety profile. This robust data, alongside recent FDA approval and EU validation for its Marketing Authorization Application, underpins VYKAT XR's position as the first commercial treatment for PWS-related hyperphagia. Analysts maintain a highly bullish outlook on SLNO, reflecting confidence in the drug's significant market potential, which has driven the stock's 116% surge over the past year.

Analysis

Soleno Therapeutics (SLNO) has reinforced the commercial case for its recently FDA-approved drug, VYKAT XR, by presenting new data demonstrating its efficacy and manageable safety profile for Prader-Willi syndrome (PWS). The data showed statistically significant reductions in hyperphagia symptoms, which were numerically greater and clinically meaningful in patients under strict food controls, with efficacy sustained through Year 3. Critically, the treatment was shown to be safe for the 60% of study participants with pre-diabetes or diabetes, a key demographic for adoption, despite a higher incidence of manageable hyperglycemia-related adverse events (42.7% vs 24.0%) and low discontinuation rates. This clinical validation follows the drug's landmark FDA approval on March 26, 2025, establishing it as the first commercial therapy for PWS-associated hyperphagia, and is further supported by the European Medicines Agency's validation of its marketing application, opening a path to the EU market. While this positive fundamental momentum has driven the stock up 116% over the past year to near its 52-week high, an InvestingPro analysis suggests it is trading above fair value. Nonetheless, analyst sentiment remains highly bullish, with price targets ranging from $97 to $145, reflecting strong confidence in the drug's monopoly position and market potential, contingent on securing favorable reimbursement agreements.

Key Decisions for Investors

• The combination of strong clinical data, first-in-class FDA approval, and European regulatory progress provides a compelling growth narrative for VYKAT XR, aligning with the bullish analyst outlook.
• Investors should weigh the strong fundamental outlook against the stock's significant 116% annual gain and an analysis indicating it may be trading above fair value, suggesting caution on entry points.
• Monitor the progress of commercial launch execution, specifically the negotiation of reimbursement agreements in the U.S. and the final EMA decision, as these are the next major catalysts for the stock.
• Closely track real-world data on the management of hyperglycemia, as the drug's long-term adoption hinges on physician confidence in its safety profile, particularly within the large patient subgroup with pre-diabetes.